Semaglutide was cost-effective in 74% of all comparisons with other diabetes drugs, but 100% of Novo Nordisk-sponsored studies found it cost-effective versus only 50% of independent studies and 0% of studies funded by other manufacturers.
100% vs 50% vs 0%Cost-effectiveness conclusions varied by sponsor: Novo Nordisk studies all favored semaglutide, independent studies split 50/50, and competitor-funded studies never found it cost-effective
What the researchers found
Across 45 articles containing 119 comparisons, semaglutide was dominant or cost-effective in 73.9% of all analyses against within-study willingness-to-pay thresholds. However, sponsor type dramatically influenced results:
- **Novo Nordisk-sponsored**: 100% found semaglutide dominant/cost-effective
- **Non-industry sponsored**: 50% found semaglutide cost-effective
- **Other industry sponsors**: 0% found semaglutide cost-effective
Semaglutide was more likely to appear cost-effective in high-income countries, studies with longer time horizons, broader perspectives, and lower discount rates. Results remained consistent when converted to a common US$50,000/QALY willingness-to-pay threshold.
Why it matters
With semaglutide becoming one of the most prescribed and expensive drugs globally, understanding its true cost-effectiveness is critical for healthcare systems. The striking difference between industry-funded and independent analyses reveals how modeling choices — time horizon, perspective, discount rate — can be tuned to produce favorable results. This finding has implications not just for semaglutide but for how we evaluate the economic value of all expensive peptide-based therapeutics.
How the study worked
Systematic review and meta-analysis searching PubMed, Embase, and the Cost-Effectiveness Analysis Registry through June 2024. Included 45 articles (119 comparisons) from Europe (24), North America (13), and Asia (8). Extracted lifetime costs and quality-adjusted life-years (QALYs). Calculated proportions for cost-effectiveness outcomes and performed subgroup analyses by region, sponsor type, comparator type, and model assumptions. Reporting quality was assessed (86.7% high quality). Nearly 69% of studies were industry-sponsored.
What this study cannot tell us
Cost-effectiveness analyses inherently rely on modeling assumptions that can significantly influence outcomes — the wide variation by sponsor type may partly reflect legitimate differences in model design rather than pure bias. The review couldn't access proprietary model details to assess exactly which assumptions drove differences. Regional economic variations make direct cross-country comparisons challenging. Most studies used a lifetime horizon (93.3%), which involves significant extrapolation beyond available clinical data. The analysis focused on diabetes, not obesity indications where cost-effectiveness may differ.
How to read the evidence
This is a well-conducted systematic review and meta-analysis of economic evaluations — the appropriate methodology for synthesizing cost-effectiveness evidence. The high reporting quality of included studies (86.7%) is a strength. However, cost-effectiveness analyses are inherently model-dependent, making them more susceptible to sponsor influence than clinical outcome trials.
When this study was published
Published in 2025 in Diabetes Care (a top-tier diabetes journal) with a search through June 2024, this is a very current synthesis of the semaglutide cost-effectiveness literature.
The bigger picture
As GLP-1 receptor agonists and other peptide drugs become the most expensive category in global pharmaceutical spending, health economics analyses increasingly determine patient access. This meta-analysis exposes a systemic problem: industry-sponsored economic models consistently favor the sponsor's product through choices in modeling assumptions. For healthcare decision-makers allocating limited budgets, understanding this bias is essential for making evidence-based coverage decisions about peptide therapeutics.
Questions still open
- Should healthcare decision-makers discount or require independent verification of industry-sponsored cost-effectiveness analyses for expensive peptide drugs?
- Would mandating standardized modeling assumptions across cost-effectiveness studies reduce the influence of sponsor bias?
- How does the cost-effectiveness of semaglutide for obesity compare to its assessment in diabetes?
Common questions
What does 'cost-effective' mean for a drug like semaglutide?
Why do industry-funded studies reach different conclusions than independent ones?
Read the original research
Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.
Diabetes care, 48(6), 1032-1041
Citation
Liu, Ziyun; Zeng, Baoqi; Sun, Feng; Xia, Qing. (2025). Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.. Diabetes care, 48(6), 1032-1041. https://doi.org/10.2337/dc24-2241